Development of Dithioacetal‐Modified Dihydropyrimidone Derivatives with Potential Anti‐Inflammatory Activity for Inflammatory Bowel Disease
Jian‐Wei Jiang, Rui Dong, Qi Cao, Huan Wang, Si‐Yu Li, Guo‐Ping Zhang, Qian‐Yi Wang · 2026
Read Development of Dithioacetal‐Modified Dihydropyrimidone Derivatives with Potential Anti‐Inflammatory Activity for Inflammatory Bowel Disease by Jian‐Wei Jiang, Rui Dong, Qi Cao, Huan Wang, Si‐Yu Li, Guo‐Ping Zhang, Qian‐Yi Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13614288.txt.
Description
Inflammatory bowel disease is a chronic autoimmune attack on the gut, and new small-molecule drugs are badly needed. A seven-author team designed a family of compounds built on a dihydropyrimidinone core with added dithioacetal groups, then screened them for safety and for calming inflammation in cell tests.
One compound, D3, stood out, blocking nitric oxide release at low dose. The team traced its action to a signaling route, the MAPK/NF-kB pathway, whose activation D3 suppresses. That lowered the output of inflammatory proteins. In mice with chemically induced colitis, D3 reduced weight loss and the sticking of the colon wall that marks severe disease. The authors conclude the family holds real promise and present D3 as a lead worth developing toward a bowel disease drug.
Catalog record
| CREATOR | Jian‐Wei Jiang, Rui Dong, Qi Cao, Huan Wang, Si‐Yu Li, Guo‐Ping Zhang, Qian‐Yi Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |